Key clinical point: Patients with bleeding post-ACS discharge had an elevated risk of a new cancer diagnosis.
Major finding: Patients with bleeding had a hazard ratio of 3.43 for a new cancer diagnosis, with highest risk within the first 6 months after an ACS.
Study details: Retrospective records review of 3,644 patients discharged with dual-antiplatelet therapy after acute coronary syndrome.
Disclosures: The authors reported no outside sources of funding, and no disclosures.
Munoz Pousa, I., et al. ESC 2019, Abstract 677.